Table 4.
Exploratory Outcomes of Annual Changes in Height-Adjusted Total Kidney Volume and Estimated Glomerular Filtration Rate
| N | Metformin Mean (SE) | Placebo Mean (SE) | p-Value | ||
|---|---|---|---|---|---|
| htTKV (full cohort; % change) | 43 (21 M; 22 P) | 3.45 (1.30) | 3.15 (1.61) | 0.88 | |
| eGFR (mL/min/1.73m2) | 43 (21 M; 22 P) | −0.41 (1.81) | −3.35 (1.70) | 0.24 | |
| Participants with baseline TKV > 600 ml/m | Treatment*Baseline htTKV Interaction | ||||
| htTKV (% Change) | 25 (13 M; 12 P) | 1.79 (1.75) | 4.73 (1.86) | 0.26 | 0.35 |
| eGFR (mL/min/1.73m2) | 25 (13 M; 12 P) | −1.29 (2.44) | −4.17 (1.96) | 0.38 | 0.83 |
| Participants with baseline TKV > 800 ml/m | Treatment*Baseline htTKV Interaction | ||||
| htTKV (% Change) | 18 (11 M; 7 P) | 0.81 (1.92) | 5.86 (0.86) | 0.03 | 0.22 |
| eGFR (mL/min/1.73m2) | 18 (11M; 7 P) | −3.00 (2.57) | −3.86 (3.22) | 0.84 | 0.24 |
| Participants in Mayo Imaging Classes 1C, 1D and 1E | Treatment*Baseline Mayo Class Interaction | ||||
| htTKV (% Change) | 26 (14 M; 12 P) | 1.92 (1.62) | 4.39 (2.43) | 0.41 | 0.76 |
| eGFR (mL/min/1.73m2) | 26 (14 M; 12 P) | −1.57 (2.50) | − 1.85 (2.35) | 0.94 | 0.52 |
M= metformin; P= placebo. P-values are based on the two-sample t-test comparing changes in parameters between the 2 groups